H.C. Wainwright raises NeuroPace stock price target to $20 on guidance

NeuroPace raised its fiscal 2026 revenue guidance to $99 million-$101 million from $98 million-$100 million after Q1 revenue rose to $22.1 million, up 20.1% year over year excluding DIXI Medical. RNS system revenue increased 18.5% to $21.7 million, and gross margin of 78% remained on track with guidance, though the company still posted a net loss of $6.7 million, or $0.20 per share. H.C. Wainwright lifted its price target to $20 from $19, matching the Wall Street consensus.

Analysis

This reads less like a re-rating event and more like a de-risking of the growth path: the market is getting higher confidence that NeuroPace can compound installed-base revenue without needing a step-change in capital intensity. The important second-order signal is that prescription and account momentum is now broad enough to support multiple quarters of mid-teens to low-20s growth, which should tighten the valuation spread versus other small-cap medtech names that still trade on one-off pipeline hopes rather than recurring utilization.

The real catalyst is not the current quarter; it is whether management can keep raising guidance while preserving gross margin expansion. If they do, operating leverage becomes visible quickly because fixed SG&A and commercial infrastructure should scale slower than revenue over the next 2-3 quarters. That matters for a name like this because once investors believe the top line is repeatable, the equity can move from being categorized as "story stock" to "self-funding growth asset," which usually expands multiple support and reduces the penalty for near-term losses.

Contrarian risk: consensus may be underestimating how much of the current optimism is already in the stock. When a small-cap medtech name hits consensus targets and reports in line-to-slightly-better, upside often stalls unless there is an earnings inflection or clear path to cash flow breakeven. The other risk is indication expansion: if the base business is strong but the next growth leg takes longer to convert into reimbursed volume, the market could start discounting the pipeline extension as delayed rather than additive.

From a trading standpoint, this is a better long-only candidate on pullbacks than a chase after strength, because the stock likely needs another guidance raise or margin beat to justify a new leg higher. Near term, the setup favors buying into post-earnings consolidation rather than front-running the next print, while protecting against a compression trade if growth slows even modestly in the next 1-2 quarters.

Key Decisions for Investors

• Initiate a tactical long in NPCE on any 5-8% post-rally pullback; target a 3-6 month hold into the next guidance update, with upside tied to another revenue raise and downside limited to failed momentum confirmation.
• Use a call spread in NPCE rather than outright stock if entering ahead of the next quarter: structure for a 2-3 month catalyst window where upside is driven by multiple expansion, not earnings profitability.
• Pair NPCE long against a lower-quality small-cap medtech name with similar valuation but weaker recurring revenue visibility; the relative-value thesis is that NeuroPace deserves a premium if utilization trends remain intact.
• If NPCE fails to show sequential account or prescriber growth next quarter, reduce exposure quickly; the stock’s multiple is vulnerable to even a small growth deceleration because current optimism is built on execution consistency.